Overview

A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-10-02
Target enrollment:
Participant gender:
Summary
This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination